|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, the simultaneous presence of both LRRK2 and BDNF variants significantly enhanced the risk for PD (OR = 4.033; 95% CI = 2.188-7.435, p < 0.0001), particularly in patients with an onset age of older than 60 (OR = 6.439; 95% CI = 3.096-13.389, p < 0.0001).
|
21924942 |
2012 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, the results of Western blot and immunofluorescence staining of BDNF indicate that pVAX-BDNF complexed with RDP can be delivered into brain, and show neuroprotective properties in experimental Parkinson's disease (PD) model.
|
23555734 |
2013 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of Parkinson's disease.
|
24051673 |
2013 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 13 case-control studies were included, involving two polymorphisms (G196A and C270T) of BDNF gene and covering 3333 PD cases and 3418 controls.
|
23611539 |
2013 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mean value for urinary extracellular neurotrophin receptor p75 from 28 amyotrophic lateral sclerosis patients measured by ELISA was 7.9±0.5 ng/mg creatinine and this was significantly higher (p<0.001) than 12 controls (2.6±0.2 ng/mg creatinine) and 19 patients with other neurological disease (Parkinson's disease and Multiple Sclerosis; 4.1±0.2 ng/mg creatinine).
|
24475283 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brain derived neurotrophic factor (BDNF) is a potent mediator of cell survival and differentiation and can reverse neuronal injury associated with Parkinson's disease (PD).
|
24374887 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the influence of SNPs in the catechol-O-methyltransferase (COMT), monoamine oxidase A (MAO-A) and brain-derived neurotrophic factor (BDNF) genes on LID in a cohort of 285 pathologically confirmed Parkinson's disease patients, using data from their complete disease course.
|
24008922 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The glial cell line-derived neurotrophic factor (GDNF), one of the most potent useful neurotrophic factors for the treatment of Parkinson's disease (PD), is firstly synthesized as the proform (proGDNF) like other neurotrophin NGF, BDNF, and NT3.
|
23934644 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
|
24633632 |
2014 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis identified an association between the BDNF 196 G/A polymorphism in Europeans, but not in Asians, but failed to identify an association between the BDNF 270 C/T polymorphism and PD.
|
24329127 |
2014 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease.
|
24394906 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study we compared monolayer-cultured (aMSC) and spheroid (sMSC) MSC following transplantation into the substantia nigra (SN) of 6-OHDA lesioned rats regarding effects on the local microenvironment, degeneration of dopaminergic neurons, neurogenesis in the hippocampal DG as well as motor and memory function in the 6-OHDA-rat model for PD. aMSC transplantation significantly increased tyrosine hydroxylase (TH) and brain-derived neurotrophic factor (BDNF) levels in the SN, increased the levels of the glial fibrillary acidic protein (GFAP) and improved motor functions compared to untreated and sMSC treated animals.
|
25120226 |
2015 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data do not support a major role for the BDNF Val66Met polymorphism in the pathogenesis of PD.
|
25431370 |
2015 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, these studies used different outcome measures, have not been replicated, and were cross sectional, making it difficult to establish the role of BDNF in the clinical variability of PD.
|
25444596 |
2015 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest a role for BDNF Val66Met polymorphism on cognitive impairment in PD.
|
26806863 |
2016 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixteen polymorphisms in candidate genes belonging to five neurotransmitter systems (dopaminergic, catecholaminergic, serotonergic, glutamatergic, opioidergic) and the BDNF were screened in 154 PD patients with addictive behaviors and 288 PD control subjects.
|
27237108 |
2016 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that a combination of DHA and ASA could significantly improve the expression of PSD-95, BDNF, and GDNF by promoting heterodimerization of PPARα and RXRα, thus supplying a new therapeutic method for PD.
|
28346830 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of exposure to an enriched environment (EE) on motor, cognitive and neuronal (levels of tyrosine hydroxylase, TH and brain derived neurotrophic factor, BDNF) deficits induced by a progressive model of Parkinson's disease (PD) in mice.
|
28432010 |
2017 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several genetic studies have shown a significant association between schizophrenia, Alzheimer's disease, and Parkinson's disease and certain BDNF polymorphisms, specifically rs6265;rs759834365" genes_norm="627">G196A (rs6265) and C270T (rs56164415).
|
28539884 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the brain release of neurotrophic factors (including brain-derived neurotrophic factor) is partially exercise related, the marked reduction in exercise may contribute to the increasing prevalence of PD.
|
28507529 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The brain-derived neurotrophic factor (BDNF) is involved in metabolic syndrome (MetS) and neurodegenerative diseases (NDD) like Alzheimer's disease, Huntington's disease, Parkinson's disease and depression.
|
28361262 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using the "weaver" mouse, a genetic model of PD, which exhibits progressive dopaminergic neurodegeneration in the Substantia Nigra (SN), we have shown that long-term administration (P1-P21) of BNN-20 almost fully protected the dopaminergic neurons and their terminals, via i) a strong anti-apoptotic effect, probably mediated through the Tropomyosin receptor kinase B (TrkB) neurotrophin receptor's PI3K-Akt-NF-κB signaling pathway, ii) by exerting an efficient antioxidant effect, iii) by inducing significant anti-inflammatory activity and iv) by restoring Brain-Derived Neurotrophic Factor (BDNF) levels.
|
28461162 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
|
27915043 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease.
|
28634349 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Association Between Physical Activity With Cognitive Function and Brain-Derived Neurotrophic Factor in People With Parkinson's Disease: A Pilot Study.
|
28338380 |
2017 |